We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.20
Bid: 2.10
Ask: 2.18
Change: 0.00 (0.00%)
Spread: 0.08 (3.81%)
Open: 2.19
High: 2.20
Low: 2.19
Prev. Close: 2.14
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

Fri, 06th May 2022 19:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Mpac Group PLC - Coventry, England-based packaging company - Says trading in 2022 so far has been in line with expectations. Explains the prospects pipeline is strong and its current order book is "significantly" above the previous year. However, company notes that supply chain uncertainties and operational challenges have increased, amplified by transportation delays. Mitigation measures in place and thus company remains positive. Chief Executive Tony Steels says he expects the full-year to be in line with expectations.

----------

Primorus Investments PLC - London-based investment firm focused on small and mid cap firms in financial services, technology and natural resources - Signs a deed of amendment which extends the time for investee Alteration Earth PLC to complete its prospectus and obtain its listing on the London Stock Exchange. Date has been extended to June 6 from May 4.

----------

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Receives notice Acacia Research Corp that it has increased its ownership of the company. Acacia acquires a further 646,932 shares representing 21% of Arix's share capital. Acacia also notifies Arix that it does not intend to make an offer for the company.

----------

Gunsynd PLC - London-based investment company focused on the natural resources, life sciences and alcohol sector - Gives notice to Sajawin Pty Ltd to terminate the term sheet and variation terms sheet in relation to the disposal of Gunsynd's shareholding in Oyster Oil & Gas Ltd. Gunsynd, in conjunction with other shareholders in Oyster, will now seek alternative avenues to monetise the project.

----------

Pantheon Resources PLC - London-based oil and gas company focused on Alaska - Announces that the holder of its senior unsecured convertible bonds due 2026 has exercised conversion rights for USD3.8 million. Accordingly, the remaining amount under the convertible bonds will be reduced to USD46.6 million.

----------

Open Orphan PLC - London-based pharmaceutical services company - Notes market speculation regarding its potential delisting. Confirm it has no plans to delist and says it is working with Liberum Capital to complete its due diligence.

Separately, company says its subsidiary, hVIVO, has signed a "substantial" contract with an unnamed pharmaceutical client. Contract is manufacture a virus for use in human challenge studies. Adds that virus manufacturing activities have commenced and expected to be completed by the end of the third quarter of 2022. Revenue for the manufacturing process will be recognised in 2022, company says.

----------

Insig AI PLC - London-based data science and machine learning company - Signs agreement for a GBP1.0 million convertible loan note. Note provided by Non-Executive Chair Richard Bernstein. Loan is unsecured and repayable on or before December 31. An initial tranche of GBP250,000 has been drawn down.

----------

Enwell Energy PLC - London-based oil and gas company - Says SV-31 well is currently producing at a stabilised flow rate of 2.7 million standard cubic feet per day of gas and 185 barrels per day of condensate. All operations remain suspended at the Vasyschevskoye gas and condensate field and the Svystunivsko-Chervonolutskyi exploration licence in light of Russian military action in Ukraine. Chief Executive Sergii Glazunov says: "We are very pleased with the results of the SV-31 well, which was drilled safely and successfully, and ahead of schedule. The completion of the well in the current extremely challenging environment in Ukraine is a great achievement by our team, and the strong flow rates recorded will provide a welcome boost to our overall production volumes."

----------

ImmuPharma PLC - London-based drug discovery and development company - Confirms that final preparations are underway to progress Lupuzor into a new phase three trial for lupus patients. Adds that its US partner Avion Pharmaceuticals have confirmed they are requesting final guidance from the US Food & Drug Adminstration to commence the phase three trial. Chief Executive Tim McCathy says: "Following the positive readout from the [pharmacokinetic] study, we have been working closely with the team at Avion to move Lupuzor as quickly as possible to the start of the Phase 3 trial."

----------

SDX Energy PLC - London-based oil and gas company focused on Egypt and Morocco - Completes tie-in of the SD-5X Warda well one month ahead of schedule. The company holds a 37% working interest in the well. Well is now under production test, with first gas achieved on April 27. After the initial flow period, there will be a shut-in of 12 hours followed by a main flow period of five days. Post the main flow period, the well will be shut in for 10 days to monitor the pressure build-up. Chief Executive Mark Reid says: "The well is now contributing to production and cash flow from this asset much earlier than originally anticipated... Once the long-term production profile for the well has been established, we will revise our 2022 production guidance if appropriate."

----------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - Reports drilling at its Laguna Verde and Francisco Basin. Two drill rigs are now in operation at the Francisco Basin. Upgrades resource estimate for Laguna Verde. Maiden resource estimate for Francisco Basin on track for the second quarter of 2022. Chief Executive Aldo Boitano says: "The resource drilling programmes, which commenced in January 2022 at Laguna Verde and in March 2022 at Francisco Basin, continue to progress well. The Francisco Basin programme has been accelerated with the addition of the second rig, bringing the total number of rigs operating across both sites to three."

----------

Caerus Mineral Resources PLC - Cyprus-based exploration & resource development company focussed on Europe - Returns "consistently anomalous" gold assay results from hand auger drilling and pitting results for the Mala pyrite dump in Cyprus. Reports peak gold grades 9.9 grams per tonne of gold, 1.3 grams per tonne of gold and 1.2 grams per tonne of gold. A total of 55 auger holes and pits return gold grades from 0.1 to 9.9 grams per tonne of gold. Chief Executive Martyn Churchouse says: "The potential gold resource in the pyrite dumps combined with the known sulphide body is an excellent start and provides the confidence we need to commit to further detailed resource development."

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Apr 2024 12:52

Immupharma jumps amid new IP strategy for P140 technology platform

(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.

Read more
25 Mar 2024 12:20

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 10:55

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
6 Mar 2024 13:05

EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up

(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Dec 2023 17:52

EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Dec 2023 12:18

IN BRIEF: Incanthera signs skincare stocking deal, raises GBP1 million

Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise.

Read more
7 Sep 2023 17:07

TRADING UPDATES: RA International loss narrows as revenue grows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
31 Aug 2023 13:05

ImmuPharma launches GBP2 million fund raise as interim loss narrows

(Alliance News) - ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under GBP2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses.

Read more
21 Aug 2023 12:33

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

(Alliance News) - Incanthera PLC and ImmuPharma PLC on Monday agreed a 12 month extension to their warrant instrument.

Read more
23 Jun 2023 15:51

UK shareholder meetings calendar - next 7 days

Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
Thursday 29 June 
3i Group PLCAGM
Africa Opportunity Fund LtdAGM
Anemoi International LtdAGM
Anpario PLCAGM
Ariana Resources PLCAGM
Beowulf Mining PLCAGM
Celadon Pharmaceuticals PLCAGM
Cornish Metals IncAGM
East Imperial PLCAGM
East Star Resources PLCAGM
Eden Research PLCAGM
Engage XR Holdings PLCAGM
First Class Metals PLCAGM
Gresham House Energy Storage Fund PLCGM re remuneration policy
Gusbourne PLCAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Ingenta PLCAGM
IQE PLCAGM
Kooth PLCAGM
Landore Resources LtdAGM
Let's Explore Group PLCAGM
Likewise Group PLCAGM
MGC Pharmaceuticals LtdGM re issue of convertible notes
Morgan Advanced Materials PLCAGM
NetScientific PLCAGM
New Century AIM VCT 2AGM
Norman Broadbent PLCAGM
Reabold Resources PLCAGM
Rockhopper Exploration PLCAGM
Roquefort Therapeutics PLCAGM
Serica Energy PLCAGM
SpaceandPeople PLCAGM
Symphony Environmental Technologies PLCAGM
Synairgen PLCAGM
Thalassa Holdings LtdAGM
tinyBuild IncAGM
Touchstone Exploration IncAGM
Trident Royalties PLCAGM
Unigel Group PLCAGM
Verici Dx PLCAGM
Xpediator PLCAGM
Friday 30 June 
Argo Blockchain PLCAGM
Ascent Resources PLCAGM
Bluejay Mining PLCAGM
Caspian Sunrise PLCAGM
Codex Acquisitions PLCAGM
Domino's Pizza Group PLCGM re directors' remuneration policy
Fenikso LtdAGM
Fiinu PLCAGM
FireAngel Safety Technology Group PLCAGM
GENinCode PLCAGM
Hemogenyx Pharmaceuticals PLCAGM
Hiro Metaverse Acquisitions I SAAGM
i3 Energy PLCGM re premium share cancellation
ImmuPharma PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kefi Gold & Copper PLCAGM
Kistos Holdings PLCAGM
KRM22 PLCAGM
Kropz PLCAGM
LoopUp Group PLCAGM
Medica Group PLCAGM
Mirriad Advertising PLCAGM
Rockfire Resources PLCAGM
Savannah Energy PLCAGM
Strip Tinning Holdings PLCAGM
ThomasLloyd Energy Impact Trust PLCAGM
URA Holdings PLCAGM
World Chess PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jun 2023 12:02

IN BRIEF: ImmuPharma to start next two phases of Lupuzor trial

ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food & Drug Administration. Says the clinical trial will be supported by Avion Pharmaceuticals. Adds further details of the trial will be shared at a later stage. Lupuzor, or P140, is a potential treatment for Lupus disease.

Read more
18 May 2023 12:12

IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus.

Read more
11 May 2023 11:48

IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market."

Read more
19 Apr 2023 15:40

IN BRIEF: ImmuPharma says US FDA confirms date for Lupuzor meeting

ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.